Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

747
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
747
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.4K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.4K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Molecular mechanisms of coronary microembolization-induced MINOCA.

Basic research in cardiology·2026
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population.

European heart journal·2026
Same author

Realizing the full potential of registry-based randomized controlled trials.

Journal of clinical epidemiology·2026
Same author

Authors' reply: Poor long-term cardiovascular risk factor management after acute coronary syndrome: An observational cohort study.

Journal of internal medicine·2026
Same author

Mental disorders, psychotropic drug dispensation and unfavourable sociodemographic factors in patients with myocardial infarction with and without obstructive coronary arteries.

International journal of cardiology. Cardiovascular risk and prevention·2026

相关实验视频

Updated: Jan 11, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K

心肌梗塞后的β-阻塞剂与正常的喷射分数.

Anna Meta Dyrvig Kristensen1, Xavier Rossello2,3,4,5, Dan Atar6,7

  • 1Department of Cardiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen.

The New England journal of medicine
|November 10, 2025
PubMed
概括

在心肌梗塞后保持左心室喷射分数 (LVEF) 的患者中,β-阻断剂治疗没有显著降低死亡,心肌梗塞或心力衰竭的风险. 这一发现挑战了在这个特定的患者群体中常规使用β抑制剂.

更多相关视频

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.6K
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

28.6K

相关实验视频

Last Updated: Jan 11, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K
Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.6K
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

28.6K

科学领域:

  • 心脏病学 心脏病学
  • 临床试验 临床试验
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 在心肌梗塞后患有保存左心室喷射分数 (LVEF) 的患者中,β阻塞剂的疗效仍然不确定.
  • 目前的指导方针并不总是建议对所有心肌梗塞后患者进行β阻塞疗法,特别是那些正常LVEF的患者.

研究的目的:

  • 评估贝塔阻断剂治疗在患有心肌梗塞和左心室喷射率 (LVEF) 至少50%的患者中的有效性.
  • 为了确定β-阻塞剂是否会降低这一特定人群中死亡,心肌梗塞或心力衰竭的复合终点.

主要方法:

  • 五项随机对照试验的个人患者数据元分析.
  • 纳入标准:最近的心肌梗塞,LVEF ≥50%,没有其他β-阻断剂的指示.
  • 主要终点:综合所有死因,心肌梗塞或心力衰竭,使用Cox比例风险模型进行分析.

主要成果:

  • 分析了17,801名患者 (8831人接受β阻塞剂,8970人没有),随访时间中位数为3.6年.
  • 在β-阻断剂和非β-阻断剂组之间的初级复合终点没有显著差异 (HR,0.97;95% CI,0.87-1.07).
  • 对所有死因,心肌梗塞和心力衰竭的亚组分析也显示没有显著的益处.

结论:

  • 在患有心肌梗塞和保持LVEF的患者中,β-阻断剂治疗没有显示死亡,心肌梗塞或心力衰竭的复合终点的减少.
  • 这些发现表明,在没有其他令人信服的迹象的情况下,常规使用β-阻断剂可能对心肌梗塞和LVEF50%或以上的患者无益.